U.S. Breast Cancer Drugs Market Size & Outlook, 2023-2030
U.S. breast cancer drugs, 2018-2030 (US$M)
Related Markets
U.S. breast cancer drugs highlights
- The U.S. breast cancer drugs generated a revenue of USD 2,808.0 million in 2023 and is expected to reach USD 4,101.9 million by 2030.
- The U.S. market is expected to grow at a CAGR of 5.6% from 2024 to 2030.
- In terms of segment, targeted therapy was the largest revenue generating therapy in 2023.
- Immunotherapy is the most lucrative therapy segment registering the fastest growth during the forecast period.
Breast cancer drugs data book summary
| Market revenue in 2023 | USD 2,808.0 million |
| Market revenue in 2030 | USD 4,101.9 million |
| Growth rate | 5.6% (CAGR from 2023 to 2030) |
| Largest segment | Targeted therapy |
| Fastest growing segment | Immunotherapy |
| Historical data | 2018 - 2022 |
| Base year | 2023 |
| Forecast period | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Chemotherapy, Immunotherapy, Targeted Therapy, Hormonal Therapy |
| Key market players worldwide | Novartis AG ADR, Pfizer Inc, Merck KGaA, Janssen Pharmaceuticals, Celgene, Roche Holding AG, AstraZeneca PLC, AbbVie Inc, Bristol-Myers Squibb Co, Macrogenics Inc, Celldex Therapeutics Inc, Sanofi SA, Amgen Inc |
Other key industry trends
- In terms of revenue, U.S. accounted for 32.7% of the global breast cancer drugs in 2023.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In North America, U.S. breast cancer drugs is projected to lead the regional market in terms of revenue in 2030.
- Canada is the fastest growing regional market in North America and is projected to reach USD 664.3 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Breast Cancer Drugs Scope
Breast Cancer Drugs Companies
| Name | Profile | # Employees | HQ | Website |
|---|
U.S. breast cancer drugs outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to breast cancer drugs will help companies and investors design strategic landscapes.
Targeted therapy was the largest segment with a revenue share of 64.24% in 2023. Horizon Databook has segmented the U.S. breast cancer drugs based on chemotherapy, immunotherapy, targeted therapy, hormonal therapy covering the revenue growth of each sub-segment from 2018 to 2030.
The U.S. is the largest market for breast cancer drugs owing to local presence of key manufacturers in the country, high awareness & adoption, and well-established healthcare infrastructure. Increasing incidence of breast cancer in the country is one of the major factors expected to boost market growth.
According to estimates published in the Breast Cancer Facts & Figures 2019-2020 report by the American Cancer Society, in 2019, around 268,600 invasive cases and approximately 41,760 deaths were reported among women in the U.S.
Reasons to subscribe to U.S. breast cancer drugs databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of U.S. breast cancer drugs databook
-
Our clientele includes a mix of breast cancer drugs companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the U.S. breast cancer drugs, including forecasts for subscribers. This country databook contains high-level insights into U.S. breast cancer drugs from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
U.S. breast cancer drugs market size, by therapy, 2018-2030 (US$M)
U.S. Breast Cancer Drugs Share, 2023 & 2030 (US$M)
Related industry reports
Related regional statistics
No records
No related regions found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
